Influence of chronic disease long prescription management on treatment efficacy in hypertensive patients during COVID-19 epidemic period.

Objective To explore the influence of chronic disease long prescription management on the treatment effect of the patients with hypertension during the novel coronavirus pneumonia（COVID-19) epidemic period. Methods Eighty patients with hypertension chronic disease and with relatively stable condition, suitable for long medication and documented management in the outpatient department of a hospital from May 2020 to April 2021 were selected and randomly divided into the long term prescription treatment group and conventional treatment group, 40 cases in each group by using a simple randomized sampling method. The two groups conducted the standard management and 1-year follow up.The systolic blood pressure, diastolic blood pressure, body mass index (BMI),satisfaction rate, visit time and cumulative visit times were compared between the two groups, and then the blood pressure control rate was calculated. Results There were no statistically significant differences in the systolic and diastolic blood pressure, blood pressure control and BMI at the first time and final follow up between the two groups（P＞0.05）;the satisfaction rate of the patients in the long prescription treatment group was significantly higher than that in the routine treatment group（P＜0.05）,while the visiting time and cumulative visiting number in the long prescription treatment group were significantly lower than those in the routine treatment group, and the difference was statistically significant（P＜0.05）.Conclusion Compared with the conventional treatment method, the chronic disease long prescription will not have an impact on the treatment effect and safety in the patients with hypertension, but it could effectively shorten the visiting time of the patients, reduce the number of visits, effectively improve the satisfaction rate of the patients, help to improve the treatment compliance of the patients and promote the prognosis of the disease. (English) [ FROM AUTHOR] 目的 探索新型冠状病毒感染疫情防控期间慢病长处方管理对高血压患者疗效的影响. 方法 选取2020年5月至2021年4月在某院门诊就诊的病情相对稳定、适合长期服药, 并且已建档管理的高血压慢性病患者80例, 通过简单随机化抽样方法, 将抽样样本随机分为长处方治疗组和常规治疗组, 每组40例. 2组均规范管理, 随访1年. 比较2组患者收缩压、舒张压、体重指数、满意率、就诊时间和累积就诊次数, 计算血压控制率. 结果 2组患者首次及终末随访收缩压、舒张压、血压控制情况、体重指数比较, 差异均无统计学意义（P＞0.05）;长处方治疗组患者满意率明显高于常规治疗组, 就诊时间和累积就诊次数均明显低于常规治疗组, 差异均有统计学意义（P＜0.05) . 结论 与常规治疗方法比较, 慢病长处方不会对高血压患者疗效、安全性产生影响, 但能有效缩短患者就诊时间, 减少其就诊次数, 有效改善患者的满意度, 有助于提高患者治疗的依从性, 促进疾病转归. (Chinese) [ FROM AUTHOR] Copyright of Journal of Modern Medicine & Health is the property of Journal of Modern Medicine & Health and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants.

Novel immune escape variants have emerged as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. Many of the variants cause breakthrough infections in vaccinated populations, posing great challenges to current antiviral strategies targeting the immunodominance of the receptor-binding domain within the spike protein. Here, we found that a novel broadly neutralizing monoclonal antibody (mAb), G5, provided efficient protection against SARS-CoV-2 variants of concern (VOCs) in vitro and in vivo. A single dose of mAb G5 could significantly inhibit the viral burden in mice challenged with the mouse-adapted SARS-CoV-2 or SARS-CoV-2 Omicron BA.1 variant, as well as the body weight loss and cytokine release induced by mouse-adapted SARS-CoV-2. The refined epitope recognized by mAb G5 was identified as 1148 FKEELDKYF1156 in the stem helix of subunit S2. In addition, a human-mouse chimeric mAb was generated based on the variable region of heavy chain and VL genes of mAb G5. Our study provides a broad antibody drug candidate against SARS-CoV-2 VOCs and reveals a novel target for developing pan-SARS-CoV-2 vaccines.

Evaluation of Dance Therapy for Patients with Depression

Background: COVID-19 has the characteristics of strong contagion, rapid spread, and general susceptibility to the population. People work and study in high-risk and high-stress environments with their emotions in a low state, which greatly increases the probability of depression. Dance therapy, as a novel treatment for mental illness, originates from the integrated development of modern dance art and psychology. Dance therapy is one of the most effective therapies for mental illness and attracts the attention of many scholars at home and abroad. It is increasingly accepted and valued by people nowadays. Subjects and methods: This paper conducts a two-month moderate-intensity dance therapy on 65 adults with depression. Analysis is carried out on the specific effect of dance therapy with depression patients during the COVID-19. Methods of mathematical statistics is adopted by the study. Result(s): The overall depression severity of women is higher than that of men (t = -2.025, P < 0.05) at the 95% confidence level. There is a significant difference in depression at the 0.001 level before and after dance therapy (t = 22.059, P < 0.001). The participation degree in dance therapy affects the therapeutic effect of dance therapy at a significant level of 0.001 (t = 10.108, P < 0.001). Conclusion(s): The overall depression severity of patients is affected by gender and pandemic awareness level and the overall depression severity of women is higher than that of men during the COVID-19. The higher the pandemic awareness level, the lower the depression degree. Dance therapy can effectively improve depression, which is affected by the participation degree in dance therapy. The higher the participation degree, the better the therapeutic effect. Copyright © Medicinska naklada - Zagreb, Croatia.

Effect of Dance Performance on Adjuvant Therapy for Depression Patients

Background: Since the outbreak of the COVID-19 epidemic, the overall proportion of patients with depression has been increasing. Dance therapy is a kind of expressive art therapy and has a good effect on the treatment of mental diseases. In China, there is still a lack of research on the treatment of depression by dance therapy. This study explores the effect of dance therapy on the adjuvant treatment of depression patients through experimental and statistical analysis. Subjects and methods: The study selected 124 patients with depression as research subjects. Under the circumstance that the patients have received conventional drug treatment and psychological support care, the test groups received an additional adjuvant dance therapy of different frequencies for one month. A total of seven tests were conducted before and after. The HAMD scale was used to test the depression status of the patients, and the statistical tool SPSS27.0 was used to analyze the experimental data. Result(s): The data of the test group 1 and the control group showed a difference at the 0.05 significance level (t = -2.955, P = 0.025 < 0.05). The data of the test group 2 and the control group showed a difference at the 0.01 significance level (t = 4.086, P = 0.006 < 0.01). The data between the test group 3 and the control group was significantly different at 0.05 level (t = 3.437, P = 0.014 < 0.05). Before and after dance treatment, the GSES scores of patients in each test group were significantly different at 0.001 level. Conclusion(s): Dance therapy can effectively relieve the depression of patients, and has a good auxiliary effect on the current drug therapy or psychological therapy for patients. In addition, the effect of dance therapy for a long time of 30-45 minutes is better than that of a short period. Copyright © Medicinska naklada - Zagreb, Croatia.

Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China.

The aim of our study was to evaluate the therapeutic effect of antiviral drugs on coronavirus disease 2019 (COVID-19) pneumonia. Patients confirmed with COVID-19 pneumonia were enrolled and divided into seven groups according to the treatment option. Information including age, sex, and duration from illness onset to admission, clinical manifestations, and laboratory data at admission, and length of hospital stay were evaluated. The chest computed tomography (CT) imaging obtained at admission and after a 5-day treatment cycle were assessed. The clinical symptoms and laboratory tests at discharge were also assessed. At admission, no significant differences were found among the groups, including the duration from illness onset to admission, clinical symptoms, and main laboratory results. No significant differences were found among the groups in terms of the proportion of patients with pneumonia resolution (P = .151) after treatment or the length of hospital stay (P = .116). At discharge, 7 of 184 (4%) patients had a mild cough while their other symptoms had disappeared, and the proportion of patients with abnormal liver function and with increased leukocytes, neutrophils or erythrocyte sedimentation rate among the 184 patients were close to those at admission. According to the results, the inclusion of antiviral drugs in therapeutic regimens based on symptomatic treatment had no significant additional impact on the improvement in COVID-19 patients. In addition, the results of chest CT imaging, clinical manifestations, and laboratory tests at discharge were not completely consistent.

Potential Therapeutic Effect of Traditional Chinese Medicine on Coronavirus Disease 2019: A Review.

The Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 has been rapidly spreading globally and has caused worldwide social and economic disruption. Currently, no specific antiviral drugs or clinically effective vaccines are available to prevent and treat COVID-19. Traditional Chinese medicine (TCM) can facilitate syndrome differentiation and treatment according to the clinical manifestations of patients and has demonstrated effectiveness in epidemic prevention and control. In China, TCM intervention has helped to control the epidemic; however, TCM has not been fully recognized worldwide. In this review, we summarize the epidemiology and etiological characteristics of severe acute respiratory syndrome coronavirus 2 and the prevention and treatment measures of COVID-19. Additionally, we describe the application of TCM in the treatment of COVID-19 and the identification of small molecules of TCM that demonstrate anti-coronavirus activity. We also analyze the current problems associated with the recognition of TCM. We hope that, through the contribution of TCM, combined with modern technological research and the support of our international counterparts, COVID-19 can be effectively controlled and treated.

Impacts of Type 2 Diabetes on Disease Severity, Therapeutic Effect, and Mortality of Patients With COVID-19.

PURPOSE: Coronavirus disease 2019 (COVID-19) has become a topic of concern worldwide; however, the impacts of type 2 diabetes mellitus (T2DM) on disease severity, therapeutic effect, and mortality of patients with COVID-19 are unclear. METHODS: All consecutive patients with COVID-19 admitted to the Renmin Hospital of Wuhan University from January 11 to February 6, 2020, were included in this study. RESULTS: A total of 663 patients with COVID-19 were included, while 67 patients with T2DM accounted for 10.1% of the total. Compared with patients with COVID-19 without T2DM, those with T2DM were older (aged 66 years vs 57 years; P < 0.001) and had a male predominance (62.7% vs 37.3%; P = 0.019) and higher prevalence of cardiovascular diseases (61.2% vs 20.6%; P < 0.001) and urinary diseases (9% vs 2.5%; P = 0.014). Patients with T2DM were prone to developing severe (58.2% vs 46.3%; P = 0.002) and critical COVID-19 (20.9% vs 13.4%; P = 0.002) and having poor therapeutic effect (76.1% vs 60.4%; P = 0.017). But there was no obvious difference in the mortality between patients with COVID-19 with and without T2DM (4.5% vs 3.7%; P = 0.732). Multivariate logistic regression analysis identified that T2DM was associated with poor therapeutic effect in patients with COVID-19 (odd ratio [OR] 2.99; 95% confidence interval [CI], 1.07-8.66; P = 0.04). Moreover, having a severe and critical COVID-19 condition (OR 3.27; 95% CI, 1.02-9.00; P = 0.029) and decreased lymphocytes (OR 1.59; 95% CI, 1.10-2.34; P = 0.016) were independent risk factors associated with poor therapeutic effect in patients with COVID-19 with T2DM. CONCLUSIONS: T2DM influenced the disease severity and therapeutic effect and was one of the independent risk factors for poor therapeutic effect in patients with COVID-19.

[Impact of the Timing of Traditional Chinese Medicine Therapy on the Therapeutic Effect and Prognosis of Severe Coronavirus Disease 2019].

Objective To explore the optimal therapy time for the treatment of severe coronavirus disease 2019(COVID-19)by traditional Chinese medicine(TCM)and its influence on the therapeutic effect and prognosis. Methods The clinical data,laboratory findings,and outcomes of 64 patients with severe COVID-19 treated with TCM and western medicine in Chongqing from January 20,2020, to March 11,2020 were retrospectively analyzed.Patients were divided into early intervention group[TCM was initiated within 3 days (including day 3) after the first diagnosis of severe type/critical type COVID-19]and late intervention group[TCM was initiated after 7 days (including day 7) after the first diagnosis of severe type /critical type COVID-19].The changes in clinical parameters during the course of disease were compared between the two groups. Results On day 14,the oxygenation index was 292.5(252.0,351.0)mmHg in the early intervention group,which was significantly higher than that in the late intervention group [246.0(170.0,292.5)mmHg](P=0.005).The length of hospital stay [(18.56±1.11)d vs.(24.87±1.64)d,P=0.001],duration of ICU stay [(14.12±0.91)d vs.(20.00±1.53)d,P=0.000] and time to negativity [(16.77±1.04)d vs.(22.48±1.66)d,P=0.001] in the early intervention group were significantly shorter than those in the late intervention group.The intubation rate(7.3%)in the early intervention group was significantly lower than that in the late intervention group(30.4%)(P=0.028). Conclusion Early TCM therapy within three days after a diagnosis of severe COVID-19 can shorten the length of hospital stay,duration of ICU stay,and time to negativity and decrease intubation rate.

Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.

BACKGROUND: The World Health Organization characterized the Coronavirus disease 2019 (COVID-19) as a pandemic on March 11th. Many clinical trials on COVID-19 have been registered, and we aim to review the study characteristics and provide guidance for future trials to avoid duplicated effort. METHODS: Studies on COVID-19 registered before March 3rd, 2020 on eight registry platforms worldwide were searched and the data of design, participants, interventions, and outcomes were extracted and analyzed. RESULTS: Three hundred and ninety-three studies were identified and 380 (96.7%) were from mainland China, while 3 in Japan, 3 in France, 2 in the US, and 3 were international collaborative studies. Two hundred and sixty-six (67.7%) aimed at therapeutic effect, others were for prevention, diagnosis, prognosis, etc. Two hundred and two studies (51.4%) were randomized controlled trials. Two third of therapeutic studies tested Western medicines including antiviral drugs (17.7%), stem cell and cord blood therapy (10.2%), chloroquine and derivatives (8.3%), 16 (6.0%) on Chinese medicines, and 73 (27.4%) on integrated therapy of Western and Chinese medicines. Thirty-one studies among 266 therapeutic studies (11.7%) used mortality as primary outcome, while the most designed secondary outcomes were symptoms and signs (47.0%). Half of the studies (45.5%) had not started recruiting till March 3rd. CONCLUSION: Inappropriate outcome setting, delayed recruitment and insufficient numbers of new cases in China implied many studies may fail to complete. Strategies and protocols of the studies with robust and rapid data sharing are warranted for emergency public health events, helping the timely evidence-based decision-making.